Journal Watch · Frontiers in Immunology · 2026

AS01<sub>B</sub>-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a <i>post-hoc</i> cross-protocol comparison of results from HVTN 100, 107, 120, and 702.

These findings support AS01<sub>B</sub> as a superior adjuvant for HIV vaccine development, relative to MF59 and Alum.

Menezes F, Chen S, Grunenberg N et al.Frontiers in Immunology4 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1768201PMID: 41909709Study type: randomised / controlled clinical trial

TL;DR

These findings support AS01<sub>B</sub> as a superior adjuvant for HIV vaccine development, relative to MF59 and Alum.

Key findings

  • AS01<sub>B</sub> also showed a trend toward greater reactogenicity, though this difference did not reach statistical significance.
  • Importantly, no serious adverse events occurred in any of the groups.<h4>Conclusion</h4>The AS01<sub>B</sub> adjuvant demonstrated superior IgG binding antibody and CD4+ T-cell responses compared with MF59 and Alum, when given with gp120 protein boost after ALVAC-HIV prime.
  • These findings support AS01<sub>B</sub> as a superior adjuvant for HIV vaccine development, relative to MF59 and Alum.

What they did

Reactogenicity and adverse event profiles were also assessed.<h4>Results</h4>AS01<sub>B</sub> elicited higher CD4+ T cell magnitudes among positive responders than either MF59 or Alum adjuvant to the 3 antigens considered: 1086, TV1, ZM96. No statistically significant differences were observed between MF59 and Alum in CD4+ T-cell responses. Regarding IgG bAb responses, AS01<sub>B</sub> induced significantly higher magnitudes among positive responders compared to both MF59 and Alum for the C.1086C V1V2 and Con 6 gp120/B antigens. Additionally, AS01<sub>B</sub> elicited greater IgG bAb responses than MF59 for gp70-96ZM651.02 V1V2 and gp70_B.CaseA V1V2, although no significant differences were found between AS01<sub>B</sub> and Alum for these antigens.

Full abstract (original)

Background: <h4>Introduction</h4>Vaccine adjuvants are crucial in HIV vaccine development, enhancing immune responses. Immune responses generated by different adjuvanted vaccines are rarely compared directly with the same vaccine antigens.<h4>Methods</h4>This retrospective cross-protocol, cross-sectional analysis examined four randomized, controlled, double-blinded, multicenter trials (HVTN 100, 107, 120, and 702) of adults without HIV who received the ALVAC-HIV (vCP2438) vaccine and a bivalent gp120 protein booster with either MF59, Alum, or AS01<sub>B</sub> adjuvant. Participants received ALVAC-HIV at months 0, 1, 3, 6, and 12, and the adjuvanted protein at months 3, 6, and 12. Data from month 6.5 were compared for IgG V1V2 binding antibodies (bAb) and CD4+ T-cell responses, measured as IFN-γ and/or IL-2 expression, using Wilcoxon and Barnard's tests with FDR p-value multiplicity adjustment.

What they did: Reactogenicity and adverse event profiles were also assessed.<h4>Results</h4>AS01<sub>B</sub> elicited higher CD4+ T cell magnitudes among positive responders than either MF59 or Alum adjuvant to the 3 antigens considered: 1086, TV1, ZM96. No statistically significant differences were observed between MF59 and Alum in CD4+ T-cell responses. Regarding IgG bAb responses, AS01<sub>B</sub> induced significantly higher magnitudes among positive responders compared to both MF59 and Alum for the C.1086C V1V2 and Con 6 gp120/B antigens. Additionally, AS01<sub>B</sub> elicited greater IgG bAb responses than MF59 for gp70-96ZM651.02 V1V2 and gp70_B.CaseA V1V2, although no significant differences were found between AS01<sub>B</sub> and Alum for these antigens.

Results & conclusions: AS01<sub>B</sub> also showed a trend toward greater reactogenicity, though this difference did not reach statistical significance. Importantly, no serious adverse events occurred in any of the groups.<h4>Conclusion</h4>The AS01<sub>B</sub> adjuvant demonstrated superior IgG binding antibody and CD4+ T-cell responses compared with MF59 and Alum, when given with gp120 protein boost after ALVAC-HIV prime. These findings support AS01<sub>B</sub> as a superior adjuvant for HIV vaccine development, relative to MF59 and Alum.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1768201 · PubMed 41909709.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

These findings support AS01<sub>B</sub> as a superior adjuvant for HIV vaccine development, relative to MF59 and Alum.

What type of study is this?

It is a randomised / controlled clinical trial, published in Frontiers in Immunology in 2026. Reactogenicity and adverse event profiles were also assessed.<h4>Results</h4>AS01<sub>B</sub> elicited higher CD4+ T cell magnitudes among positive responders than either MF59 or Alum adjuvant to the 3 antigens considered: 1086, TV1, ZM96.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1768201. PubMed ID: 41909709. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Menezes F, Chen S, Grunenberg N et al.. AS01&lt;sub&gt;B&lt;/sub&gt;-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a &lt;i&gt;post-hoc&lt;/i&gt; cross-protocol comparison of results from HVTN 100, 107, 120, and 702.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1768201.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/as01-lt-sub-gt-b-lt-sub-gt-mf59-and-alum-based-adjuvants-and-hiv-vaccine-768201/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides